Manuel Montero-Odasso1,2,3, Yanina Sarquis-Adamson1, Hao Yuan Song1,2, Nick Walter Bray1,4, Frederico Pieruccini-Faria1,2, Mark Speechley3. 1. Gait and Brain Lab, Parkwood Institute and Lawson Health Research Institute, London, Ontario, Canada. 2. Department of Medicine and Division of Geriatric Medicine, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario, Canada. 3. Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada. 4. School of Kinesiology, Faculty of Health Sciences, University of Western Ontario, London, Ontario, Canada.
Abstract
BACKGROUND AND OBJECTIVES: Polypharmacy, defined as the use of five or more medications, has been repeatedly linked to fall incidence, and recently it was cross-sectionally associated with gait disturbances. Our objectives were to evaluate cross-sectional and longitudinal associations between polypharmacy and gait performance in a well-established clinic-based cohort study. We also assessed whether gait impairments could mediate associations between number of medications and fall incidence. DESIGN: Prospective cohort of community-dwelling older adults, with 5 years of follow-up. SETTING: Geriatric clinics in an academic hospital in London, ON, Canada. PARTICIPANTS: Community-dwelling older adults aged 65 and older (n = 249; 76.6 ± 8.6 y; 63% women). MEASUREMENTS: Number of medications, quantitative spatiotemporal gait parameters, and fall incidence during follow-up. RESULTS: The number of medications was cross-sectionally associated with poor gait performance (slow gait, speed p < .001; higher variability, p < .001; and higher stride, p < .001; step, p = .013, and double support times, p < .001). Prospectively, the number of medications was associated with overall gait decline (odds ratio = 1.23; 95% confidence interval [CI] = 1.13-1.33; p < .001), faster gait decline (hazard ratio = 4.62; 95%CI = 1.82-11.73; p < .001), and higher falls incidence (p = .006). These associations remained true after adjusting for age, sex, and accounting for "confounding by indication bias" by using a comorbidity propensity score adjustment. Each additional medication taken, significantly increased gait decline risk by 12% to 16% and fall incidence risk by 5% to 7%. Mediation analyses revealed that gait impairments in stride length, step length, and step width mediated the strength of the association between medications and fall incidence. CONCLUSION: Polypharmacy was cross-sectionally associated with poor gait performance and longitudinally associated with gait decline and fall incidence. Despite our use of propensity matching, confounding by indication could have influenced the results. Quantitative spatial gait parameters performance mediated the strength of the association between medications and falls, suggesting a role of gait disturbances in the medication-related falls pathway.
BACKGROUND AND OBJECTIVES: Polypharmacy, defined as the use of five or more medications, has been repeatedly linked to fall incidence, and recently it was cross-sectionally associated with gait disturbances. Our objectives were to evaluate cross-sectional and longitudinal associations between polypharmacy and gait performance in a well-established clinic-based cohort study. We also assessed whether gait impairments could mediate associations between number of medications and fall incidence. DESIGN: Prospective cohort of community-dwelling older adults, with 5 years of follow-up. SETTING: Geriatric clinics in an academic hospital in London, ON, Canada. PARTICIPANTS: Community-dwelling older adults aged 65 and older (n = 249; 76.6 ± 8.6 y; 63% women). MEASUREMENTS: Number of medications, quantitative spatiotemporal gait parameters, and fall incidence during follow-up. RESULTS: The number of medications was cross-sectionally associated with poor gait performance (slow gait, speed p < .001; higher variability, p < .001; and higher stride, p < .001; step, p = .013, and double support times, p < .001). Prospectively, the number of medications was associated with overall gait decline (odds ratio = 1.23; 95% confidence interval [CI] = 1.13-1.33; p < .001), faster gait decline (hazard ratio = 4.62; 95%CI = 1.82-11.73; p < .001), and higher falls incidence (p = .006). These associations remained true after adjusting for age, sex, and accounting for "confounding by indication bias" by using a comorbidity propensity score adjustment. Each additional medication taken, significantly increased gait decline risk by 12% to 16% and fall incidence risk by 5% to 7%. Mediation analyses revealed that gait impairments in stride length, step length, and step width mediated the strength of the association between medications and fall incidence. CONCLUSION: Polypharmacy was cross-sectionally associated with poor gait performance and longitudinally associated with gait decline and fall incidence. Despite our use of propensity matching, confounding by indication could have influenced the results. Quantitative spatial gait parameters performance mediated the strength of the association between medications and falls, suggesting a role of gait disturbances in the medication-related falls pathway.
Authors: Katherine B Santosa; Yen-Ling Lai; Chad M Brummett; Jeremie D Oliver; Hsou-Mei Hu; Michael J Englesbe; Emilie M Blair; Jennifer F Waljee Journal: J Gen Intern Med Date: 2020-08-03 Impact factor: 5.128
Authors: Amy L Shaver; Collin M Clark; Mary Hejna; Steven Feuerstein; Robert G Wahler; David M Jacobs Journal: Pharmacoepidemiol Drug Saf Date: 2021-02-16 Impact factor: 2.732
Authors: Michael B Westover; Lidia M V R Moura; Felipe J S Jones; Paula R Sanches; Jason R Smith; Sahar F Zafar; Sonia Hernandez-Diaz; Deborah Blacker; John Hsu; Lee H Schwamm Journal: Stroke Date: 2021-06-15 Impact factor: 10.170
Authors: Kristal M Riska; Sarah B Peskoe; Maragatha Kuchibhatla; Alexander Gordee; Juliessa M Pavon; Se Eun Kim; Jessica S West; Sherri L Smith Journal: Ear Hear Date: 2022 Mar/Apr Impact factor: 3.562